Lung Cancer

Certain subgroups of patients with advanced non¬–small cell lung cancer have a new frontline treatment option following the FDA's approval July 13 of gefitinib (Iressa).

Jyoti Patel, MD, of Northwestern University's Feinberg School of Medicine, talks about the subject of delaying whole brain radiation for brain metastases.

In a phase III trial the immunotherapy nivolumab (Opdivo) improved overall survival and was less toxic than docetaxel in both nonsquamous and squamous non–small cell lung cancer.

Rebecca Lehto, PhD, RN, OCN, discusses patient use of complementary modalities during treatment for advanced lung cancer.

Statin use before or after a diagnosis of lung cancer may be linked to a reduced risk of death from the disease, according to findings of a recent study which found that patients who used statins in the year before a lung cancer diagnosis had a statistically significant 12% reduction in lung cancer-specific deaths.

E-cigarettes, championed by some as a smoking-cessation tool, may actually decrease the likelihood of quitting smoking, according to a recent population-based study of 1000 smokers published in The American Journal of Public Health.

A nurse navigator–led program aimed at improving awareness, access, and uptake of low-dose CT screening for individuals at high risk of lung cancer resulted in improved screening rates with the potential to improve patient outcomes by catching the disease at its earliest stages.

Pembrolizumab (Keytruda) had an overall response rate (ORR) of 45.2% among a cohort of patients with high PD-L1-expressing non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial.

A new study has shown that men with a high fitness level in midlife are not only at a lower risk of developing lung and colorectal cancer, they're also at a lower risk of dying from cancer if they're diagnosed later in life.

Tracey L. Evans, MD, associate professor, clinical medicine, Abramson Cancer Center, University of Pennsylvania Health System, gives advice to oncology nurses on how to manage side effects in patients with lung cancer.

Common myths about lung cancer.

The FDA has approved nivolumab (Opdivo) for the treatment of patients with advanced squamous non–small cell lung cancer (NSCLC) who have progressed on or after platinum-based chemotherapy.

Results of a new study may help boost lung cancer clinical trial enrollment.

Tracey L. Evans, MD associate professor, clinical medicine, Abramson Cancer Center, University of Pennsylvania Health System, discusses the benefit of advanced lung cancer patients receiving palliative care early in their diagnosis.

Many patients choose not to call their providers, stating their fear of being labeled "drug seeking" or a "wimp," believing that since they were given no refills for their pain medication, the expectation must be that they should not need more when they run out.

The Bonnie J. Addario Lung Cancer Foundation (ALCF), in collaboration with Open Health Network (OHN), announced the launch of Lung Cancer Foundation, the first of its kind mobile application designed to empower lung cancer patients and their families.

Despite the proven benefits of SBRT for patients with inoperable stage I NSCLC, whether such patients are offered it depends on their race, insurance status, and the type of facility where they are being treated.

The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening using low-dose computed tomography (LDCT) for certain former and current smokers, a decision that could affect an estimated 4 million people.

At the 2014 Multidisciplinary Symposium in Thoracic Oncology in Chicago, Jyoti D. Patel, MD, associate professor in Medicine-Hematology/Oncology at the Feinberg School of Medicine at Northwestern University, led a breakout session on how to manage the toxicities associated with the molecular therapies used to treat patients with lung cancers.

As members of Tom Brokaw's "greatest generation," Andy's grandfathers took up smoking at an early age, but subsequently they heeded the Surgeon General's warning and quit. Cessation didn't spare either man a later diagnosis-in one case 25 years later-of terminal lung cancer.

Patients with certain lung and colorectal cancers whose physicians participated in weekly, treatment-focused tumor board meetings had improved survival and were 60% more likely to enroll in a clinical trial

Patients in one phase III trial gained 2.4 pounds of lean body mass during 12 weeks of treatment with anamorelin, and those in the second trial had an average increase in lean body mass of 1.65 pounds.

Lung cancer at any age is a catastrophic illness but it is particularly devastating when it affects young adults in the prime of their life.

New patient-reported data presented at the 2014 ASTRO Annual Meeting has shown that Manuka honey is not more effective than standard medical care for the treatment of esophagitis pain during radiation therapy.

Although lung cancer incidence is decreasing in the United States, the details about this trend are unknown.

Results of a large, pooled analysis indicate that there is a link between a number of common respiratory diseases and an increase in the risk of developing lung cancer.

Danielle Hicks, director, Patient Services and Support, Bonnie J. Addario Lung Cancer Foundation, discusses the lung cancer living room program

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population.

The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations.

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims to improve the drug development process while exploring therapeutic options for this challenging malignancy.